Dana-Farber Cancer Institute: Stomach Neoplasms trials

The registry lists 10 Stomach Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 2 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clonal Hematopoiesis Chemotherapy and Radiation Effects StudyRecruitingNCT07675967
• Resilience and Equity in Aging, Cancer, and Health (REACH)RecruitingNCT04674267Not applicable
• FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric CancerCompletedNCT01747551Phase 2Results posted
• CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerCompletedNCT01191697Phase 2Results posted
• Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerCompletedNCT00911820Phase 2Results posted
• Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric CancerCompletedNCT00394433Phase 2Results posted
• Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric CancerCompletedNCT00130689Phase 2Results posted
• Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00215514Early Phase 1
• Vinorelbine in Unresectable or Metastatic Esophageal and Gastric AdenocarcinomaCompletedNCT00215462Phase 2
• Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric CancerCompletedNCT00165464Phase 2